SCHEMBL30928

SCHEMBL30928

CCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.81
LMNA P02545 2/20 0.81
ALDH1A1 P00352 2/20 0.81
PRKD3 O94806 1/20 0.81
PRKCG P05129 1/20 0.81
PRKCB P05771 1/20 0.81
PRKCA P17252 1/20 0.81
PRKCH P24723 1/20 0.81
PRKCI P41743 1/20 0.81
PRKCE Q02156 1/20 0.81
PRKCQ Q04759 1/20 0.81
PRKCZ Q05513 1/20 0.81
PRKCD Q05655 1/20 0.81
PRKD1 Q15139 1/20 0.81
MAPK1 P28482 1/20 0.81
SMN1; SMN2 Q16637 1/20 0.81
MEN1 O00255 1/20 0.81
GMNN O75496 1/20 0.81
BLM P54132 1/20 0.81
KMT2A Q03164 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10755721 1.00 AKT1 (0.81) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL1532761 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2582886 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2734265 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10602960 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL417053 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2733343 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL4320248 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10565746 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10564175 0.99 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 814 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118103367-A Acid-labile chemotherapeutic paclitaxel compounds for the treatment of cancer 威尔德医疗有限公司 2024-05-28 CN claimed
EP-4355744-A1 ACID-LABILE CHEMOTHERAPEUTIC PACLITAXEL BASED COMPOUNDS FOR THE TREATMENT OF CANCER Veiled Therapeutics LLC (US) 2024-04-24 EP claimed
CN-117442731-A Application of SHP2 inhibitor in preparation of medicine for treating chronic thromboembolism 浙江大学医学院附属邵逸夫医院 2024-01-26 CN claimed
WO-2024014511-A1 LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE AND METHOD FOR PRODUCING SAME, AND METHOD FOR INDUCING ACQUIRED IMMUNITY IN LIVING BODY BY USING NUCLEIC ACID-ENCAPSULATED LIPID NANOPARTICLE 日油株式会社 2024-01-18 WO claimed
US-20230347016-A1 VALVE MATERIAL WITH LONG-ACTING ANTITHROMBOSIS PROPERTY AND PREPARATION METHOD THEREFOR VENUS MEDTECH (HANGZHOU) INC. (CN) 2023-11-02 US claimed
WO-2023190175-A1 LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS, AND METHOD FOR DELIVERING NUCLEIC ACID TO PERIPHERAL BLOOD MONONUCLEAR CELLS USING SAME 日油株式会社 2023-10-05 WO claimed
WO-2023190176-A1 LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME 日油株式会社 2023-10-05 WO claimed
CN-115353616-B Pegylated lipid 厦门赛诺邦格生物科技股份有限公司 2023-03-07 CN claimed
EP-4137168-A1 VALVE MATERIAL HAVING LONG-ACTING ANTITHROMBOSIS PROPERTY AND PREPARATION METHOD THEREFOR Venus MedTech (HangZhou), Inc. (CN) 2023-02-22 EP claimed
US-20230035723-A1 Treatment of Pancreatic Cancer SYNCORE BIOTECHNOLOGY CO., LTD. (TW) 2023-02-02 US claimed
EP-1444991-A1 Novel targeted compositions for diagnostic and therapeutic use IMARX PHARMACEUTICAL CORP. (US) 2004-08-11 EP claimed
US-20020028474-A1 Composition for immunohistochemical staining DAIICHI PURE CHEMICAL CO., LTD. (JP) 2002-03-07 US claimed
EP-0831932-A4 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP (US) 2000-01-12 EP claimed
EP-0935139-A1 IMMUNOHISTOCHEMICAL STAINING COMPOSITION DAIICHI PURE CHEMICALS CO., LTD. (JP) 1999-08-11 EP claimed
EP-0831932-A1 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1998-04-01 EP claimed
WO-1996040285-A1 NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE IMARX PHARMACEUTICAL CORP. (US) 1996-12-19 WO claimed
US-4814112-A Single-stage process for preparing mixed-substituted 1,2-diacyl-sn-clycero-3-phosphocholines CL PHARMA AKTIENGESELLSCHAFT (AT) 1989-03-21 US claimed
EP-0161519-B1 DERIVATIVES OF GLYCEROPHOSPHOCHOLINE AND OF GLYCEROPHOSPHOETHANOL AMINE, THEIR PREPARATION AND USE CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-06-29 EP claimed
US-4717512-A Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1988-01-05 US claimed
EP-0161519-A2 Derivatives of glycerophosphocholine and of glycerophosphoethanol amine, their preparation and use CHEMIE LINZ AKTIENGESELLSCHAFT (AT) 1985-11-21 EP claimed